News Image

Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

Provided By GlobeNewswire

Last update: Jan 30, 2024

MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Association for Cancer Research (AACR), which will be held April 5-10, 2024. The work reflects the Company’s on-going collaboration with Johns Hopkins University School of Medicine.

Read more at globenewswire.com
Follow ChartMill for more